These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 36161046)
1. Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report. Tanaka T; Sakai A; Tsujimae M; Yamada Y; Kobayashi T; Masuda A; Kodama Y World J Gastroenterol; 2022 Jul; 28(28):3732-3738. PubMed ID: 36161046 [TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab-related cholangitis with multiple fatal liver abscesses after endoscopic biliary drainage: a case report and review of the literature. Hori H; Fujita K; Nishio A; Nishijima M; Inaba M; Anami T; Matsui S; Kitamura Y; Matsuoka R; Watanabe A Clin J Gastroenterol; 2022 Apr; 15(2):475-479. PubMed ID: 35072901 [TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report. Sato K; Hayashi M; Abe K; Fujita M; Takahashi A; Ohira H Clin J Gastroenterol; 2020 Dec; 13(6):1310-1314. PubMed ID: 32643124 [TBL] [Abstract][Full Text] [Related]
4. Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report. Nabeshima S; Yamasaki M; Matsumoto N; Takaki S; Nishi Y; Kawamoto K; Taniwaki M; Ohashi N; Hattori N Cancer Treat Res Commun; 2021; 26():100270. PubMed ID: 33338849 [TBL] [Abstract][Full Text] [Related]
5. Anti programmed death-ligand 1 antibody-related cholangitis without bile duct dilation or stenosis. Azami T; Takano Y; Noda J; Yamawaki M; Yoshida E; Niiya F; Maruoka N; Ogawa T; Ichikawa W; Nagahama M Clin J Gastroenterol; 2022 Aug; 15(4):818-821. PubMed ID: 35729450 [TBL] [Abstract][Full Text] [Related]
6. Immune-related adverse event-associated sclerosing cholangitis due to immune checkpoint inhibitors: imaging findings and treatments. Okamoto K; Hijioka S; Nagashio Y; Okada M; Ohba A; Maruki Y; Kondo S; Morizane C; Ueno H; Okusaka T Jpn J Clin Oncol; 2024 Aug; 54(8):887-894. PubMed ID: 38715325 [TBL] [Abstract][Full Text] [Related]
7. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy. Hirasawa Y; Yoshimura K; Matsui H; Kubota Y; Ishida H; Arai J; Sakaki M; Oguro N; Shida M; Taniguchi M; Hamada K; Ariizumi H; Ishiguro T; Ohkuma R; Sambe T; Horiike A; Imamura CK; Shiozawa E; Wada S; Tsurutani J; Iwamoto S; Uchida N; Kiuchi Y; Tate G; Kobayashi S; Tsunoda T Medicine (Baltimore); 2021 Jun; 100(23):e25774. PubMed ID: 34114983 [TBL] [Abstract][Full Text] [Related]
8. Simultaneous occurrence of autoimmune pancreatitis and sclerosing cholangitis as immune-related adverse events of pembrolizumab. Suda T; Kobayashi M; Kurokawa K; Matsushita E BMJ Case Rep; 2021 Jun; 14(6):. PubMed ID: 34088696 [TBL] [Abstract][Full Text] [Related]
9. Resected case of eosinophilic cholangiopathy presenting with secondary sclerosing cholangitis. Miura F; Asano T; Amano H; Yoshida M; Toyota N; Wada K; Kato K; Takada T; Fukushima J; Kondo F; Takikawa H World J Gastroenterol; 2009 Mar; 15(11):1394-7. PubMed ID: 19294772 [TBL] [Abstract][Full Text] [Related]
10. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab. Yoshikawa Y; Imamura M; Yamaoka K; Kosaka Y; Murakami E; Morio K; Fujino H; Nakahara T; Okamoto W; Yamauchi M; Kawaoka T; Tsuge M; Hiramatsu A; Hayes CN; Aikata H; Fujitaka K; Arihiro K; Hattori N; Chayama K Clin J Gastroenterol; 2021 Feb; 14(1):283-287. PubMed ID: 33200345 [TBL] [Abstract][Full Text] [Related]
11. Intrahepatic segmental primary sclerosing cholangitis: report of a case. Matsumoto T; Ajiki T; Matsumoto I; Tominaga M; Hori H; Mita Y; Fujita T; Fujino Y; Suzuki Y; Ku Y; Kuroda Y Surg Today; 2006; 36(7):638-41. PubMed ID: 16794801 [TBL] [Abstract][Full Text] [Related]
12. A case of sclerosing cholangitis without pancreatic involvement thought to be associated with autoimmunity. Sawai H; Matsubayashi H; Sasaki K; Tanaka M; Kakushima N; Takizawa K; Yamaguchi Y; Ono H Intern Med; 2011; 50(5):433-8. PubMed ID: 21372453 [TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin G4-related sclerosing cholangitis mimicking hilar cholangiocarcinoma diagnosed with following bile duct resection: report of a case. Miki A; Sakuma Y; Ohzawa H; Sanada Y; Sasanuma H; Lefor AT; Sata N; Yasuda Y Int Surg; 2015 Mar; 100(3):480-5. PubMed ID: 25785331 [TBL] [Abstract][Full Text] [Related]
15. Usefulness of laparoscopy and intraductal ultrasonography in a patient with isolated immunoglobulin G4-related sclerosing cholangitis. Ohno Y; Kumagi T; Imamura Y; Kuroda T; Koizumi M; Watanabe T; Yoshida O; Tokumoto Y; Takeshita E; Abe M; Harada K; Hiasa Y Clin J Gastroenterol; 2018 Feb; 11(1):62-68. PubMed ID: 29094322 [TBL] [Abstract][Full Text] [Related]
16. Sclerosing cholangitis with autoimmune pancreatitis versus primary sclerosing cholangitis: comparison on endoscopic retrograde cholangiography, MR cholangiography, CT, and MRI. Kim JH; Byun JH; Kim SY; Lee SS; Kim HJ; Kim MH; Lee MG Acta Radiol; 2013 Jul; 54(6):601-7. PubMed ID: 23528564 [TBL] [Abstract][Full Text] [Related]